Shockwave Medical Inc
NASDAQ:SWAV
Intrinsic Value
Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. [ Read More ]
The intrinsic value of one SWAV stock under the Base Case scenario is 150.18 USD. Compared to the current market price of 329.48 USD, Shockwave Medical Inc is Overvalued by 54%.
Valuation Backtest
Shockwave Medical Inc
Run backtest to discover the historical profit from buying and selling SWAV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Solid Growth and Expansion in 2023, Positive Outlook for 2024
2023-Q4 Earnings Call
In 2023, the company achieved record results, with strong performance especially in the U.S. coronary business, which saw a 40% revenue increase year-over-year, boosted by the well-received C2+ launch. Peripheral revenue in the U.S. rose by 19%, showing stabilization despite prior authorization challenges. International business soared as well, with a 67% revenue uptick. Major gains were seen in Germany, where sales doubled due to improved reimbursement conditions, and in Japan and major European markets. Overall, gross margins reached 88% in Q4 2023. Operating expenses surged by 60%, mainly due to sales force expansion and R&D. Net income was $44.3 million, with basic and diluted earnings per share at $1.20 and $1.16, respectively. Adjusted EBITDA increased by 20% quarterly and 40% annually. For 2024, the company plans continued investments and projects an operating margin expansion of up to 100 basis points over 2023, ending the year with $990.6 million in cash and equivalents.
Balance Sheet Decomposition
Shockwave Medical Inc
Current Assets | 1.2B |
Cash & Short-Term Investments | 990.6m |
Receivables | 114.6m |
Other Current Assets | 120.2m |
Non-Current Assets | 341.3m |
Long-Term Investments | 1.6m |
PP&E | 98.6m |
Intangibles | 132.4m |
Other Non-Current Assets | 108.6m |
Current Liabilities | 104.2m |
Accounts Payable | 8.9m |
Accrued Liabilities | 83m |
Other Current Liabilities | 12.3m |
Non-Current Liabilities | 793.7m |
Long-Term Debt | 731.9m |
Other Non-Current Liabilities | 61.8m |
Earnings Waterfall
Shockwave Medical Inc
Revenue
|
730.2m
USD
|
Cost of Revenue
|
-95.4m
USD
|
Gross Profit
|
634.8m
USD
|
Operating Expenses
|
-475.7m
USD
|
Operating Income
|
159.1m
USD
|
Other Expenses
|
-11.8m
USD
|
Net Income
|
147.3m
USD
|
Free Cash Flow Analysis
Shockwave Medical Inc
What is Free Cash Flow?
SWAV Profitability Score
Profitability Due Diligence
Shockwave Medical Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Shockwave Medical Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
SWAV Solvency Score
Solvency Due Diligence
Shockwave Medical Inc's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Shockwave Medical Inc's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SWAV Price Targets Summary
Shockwave Medical Inc
According to Wall Street analysts, the average 1-year price target for SWAV is 262.7 USD with a low forecast of 166.65 USD and a high forecast of 304.5 USD.
Ownership
SWAV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SWAV Price
Shockwave Medical Inc
Average Annual Return | 64.17% |
Standard Deviation of Annual Returns | 57.21% |
Max Drawdown | -65% |
Market Capitalization | 12.2B USD |
Shares Outstanding | 36 900 000 |
Percentage of Shares Shorted | 5.9% |
SWAV News
Last Important Events
Shockwave Medical Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Shockwave Medical Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company is headquartered in Santa Clara, California and currently employs 657 full-time employees. The company went IPO on 2019-03-07. The firm is engaged in medical device treatment of atherosclerotic cardiovascular disease (atherosclerosis) through its differentiated local delivery of sonic pressure waves for the treatment of calcified plaque, which refer to as intravascular lithotripsy (IVL). Its products for the treatment of peripheral artery disease (PAD) includes Shockwave M5 IVL catheter (M5 catheter) and Shockwave S4 IVL catheter (S4 catheter). Its product for the treatment of coronary artery disease (CAD) is Shockwave C2 IVL catheter (C2 catheter). M5 catheter is a five-emitter catheter for use in its IVL System in medium vessels for the treatment of above-the-knee PAD. S4 catheter is a four-emitter catheter for use in its IVL System in small vessels for the treatment of below-the-knee PAD. C2 catheter is a two-emitter catheter for use in its IVL System for the treatment of CAD.
Contact
IPO
Employees
Officers
The intrinsic value of one SWAV stock under the Base Case scenario is 150.18 USD.
Compared to the current market price of 329.48 USD, Shockwave Medical Inc is Overvalued by 54%.